risankizumab + ABBV-382

**Risankizumab + ABBV-382** is an investigational combination therapy studied for the treatment of moderate to severe Crohn's disease in adults. Both drugs are monoclonal antibodies developed by AbbVie and are administered either as intravenous infusions or subcutaneous injections. Risankizumab selectively targets interleukin-23, inhibiting its pro-inflammatory actions; ABBV-382 is also a monoclonal antibody, but its precise molecular target and mechanism are not publicly specified, though it is likely aimed at a key inflammatory mediator relevant in Crohn's disease. The combination is intended to provide enhanced control of intestinal inflammation[1][2][3][4].